Sign in

    Marcel

    Research Analyst at Not Disclosed

    No definitive professional profile for Marcel, an analyst at Not Disclosed, was found through LinkedIn or reliable public sources. Consequently, details such as full job title, companies covered, performance metrics, career history, and professional credentials could not be verified. There is no evidence available regarding Marcel's industry specialization, investment track record, or prior experience at other firms. Due to the lack of verifiable data, a comprehensive web display paragraph cannot be provided at this time.

    Marcel's questions to RECURSION PHARMACEUTICALS (RXRX) leadership

    Marcel's questions to RECURSION PHARMACEUTICALS (RXRX) leadership • FY 2024

    Question

    Marcel raised concerns about the potential for inaccuracies or 'hallucinations' in virtual cell models, particularly for rare diseases, and asked how Recursion would validate the results from such simulations.

    Answer

    SVP, Head of Platform, Lina Nilsson, responded that they use diverse model architectures and large benchmarking datasets to ensure accuracy. Crucially, she stressed that all model-driven insights are validated in physical labs, allowing them to focus experiments on the most promising hypotheses. For rare diseases, they leverage broad biological models to provide context and confidence where data is sparse.

    Ask Fintool Equity Research AI

    Marcel's questions to RECURSION PHARMACEUTICALS (RXRX) leadership • Q2 2024

    Question

    Marcel asked about the company's efforts in preventative healthcare, specifically developing drugs or partnerships to reduce the risk of diseases like cancer or Alzheimer's.

    Answer

    CEO Christopher Gibson confirmed that preventative medicine is a core part of Recursion's vision, highlighting existing pipeline programs that target genetic predispositions to cancer. He pointed to the Roche-Genentech collaboration as a key effort in neurodegeneration. Gibson emphasized that the company's foundational belief is that its technology can map and understand biological complexity at a scale necessary to tackle the multifaceted nature of preventative medicine.

    Ask Fintool Equity Research AI